Clinical Trial Search

Primary: Best Overall Response (BOR) Until Cut-off Date 25 January 2011 — 54.4 percentage of participants

Primary: Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound…

Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs — 4; 50; 14; 2 participants

Primary: Hemoglobin A1C — -0.39; -0.26 percent — p=0.079

Primary: Number of Participants With Treatment Failure at 5 Years — 33; 19 participants

Primary: Time to Complete Healing of Each Baseline DU

Primary: Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery — 30.7; 6.5 ml/min

Primary: Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series — 100.0; 98.3; 100.0; 100.0 percentage of participants

Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 98.2; 98.2; 77.5; 87.1…

Primary: Composite Major Adverse Event (MAE) Rate of Death, Myocardial Infarction, and Stroke at 30 Days Postprocedure — 10; 2; 1; 0 Participants — p=0.0001

Primary: Change From Baseline in Hemoglobin A1C (%) at Week 24 — -0.84; -0.16 Percentage of glycosylated hemoglobin — p=<0.001

Primary: Mean Change From Baseline in Total Awake Time Spent "Off" at Week 24 Using Last Observation Carried Forward (LOCF) — -0.4; -2.1 hours — p=<0.001

Primary: Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations — 10.170; 11.424; 11.438; 11.021 microgram per milliliter (µg/mL)

Primary: American College of Rheumatology 20% (ACR20) Response at Week 12 — 62.5; 76.8; 77.6; 28.6 percentage of participants — p=<0.025

Primary: American College of Rheumatology 20% (ACR20) Response at Week 12 — 67.2; 14.9 percentage of participants — p=<0.05